Top Monthly Winners: AbbVie, Philip Morris, and More
In February 2025, stock markets fell on average. The S&P 500 (SPY) fell by 1.27%, due mostly to a decline in technology stocks. Investors reallocated their holdings into the drug sector. AbbVie (ABBV) ...
24/7 Wall St9h
Market Correction Wake-Up Call? 4 Dependable High-Yield Dividend Kings to the Rescue
Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...
Zacks.com on MSN9h
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...
Crain's Chicago Business10h
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...
Pharmabiz14h
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...